Allergy and Brain Tumors in the INTERPHONE study: Pooled Results from Australia, Canada, France, Israel, and New Zealand

Michelle C. Turner^{1,2,3}, Daniel Krewski^{1,4,5}, Bruce K. Armstrong⁶, Angela Chetrit⁷, Graham G. Giles⁸, Martine Hours⁹, Mary L. McBride¹⁰, Marie-Élise Parent¹¹, Siegal Sadetzki^{7,12}, Jack Siemiatycki¹³, Alistair Woodward¹⁴, Elisabeth Cardis^{2,3}

¹ McLaughlin Centre for Population Health Risk Assessment, Institute of Population Health, University of Ottawa, Ottawa, Canada

² Centre for Research in Environmental Epidemiology (CREAL), Barcelona, Spain

³ CIBER Epidemiología y Salud Pública (CIBERESP), Barcelona, Spain

⁴ Department of Epidemiology and Community Medicine, Faculty of Medicine, University of Ottawa, Ottawa, Canada

⁵ Risk Sciences International, Ottawa, Canada

⁶ Sydney Cancer Centre and School of Public Health, The University of Sydney, Sydney, Australia

⁷ Cancer and Radiation Epidemiology Unit, The Gertner Institute for Epidemiology and Health Policy Research, Chaim Sheba Medical Centre, Tel-Hashomer, Israel

⁸ Cancer Epidemiology Centre, Cancer Council Victoria, Melbourne, Australia and Centre for MEGA Epidemiology, School of Population Health, The University of Melbourne, Melbourne Australia

⁹ Unité Mixte de Recherche Épidémiologique Transport Travail Environnement INRETS – UCBL – InVS, Université Lyon 1, Lyon, France

¹⁰ British Columbia Cancer Agency, Vancouver, Canada

¹¹ INRS-Institut Armand-Frappier, Université du Québec, Laval, Canada

¹² Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel

¹³ University of Montreal, Montreal, Canada

¹⁴ School of Population Health, University of Auckland, Auckland, New Zealand

Corresponding Author:

Michelle C. Turner

McLaughlin Centre for Population Health Risk Assessment, Institute of Population Health, University of Ottawa

One Stewart Street, Room 313

Ottawa, Ontario, Canada

K1N 6N5

Tel: 613-562-5800 ext. 2328

Fax: 613-562-5380

Email: mturner@uottawa.ca

Competing Interests:

The authors have no conflict of interest to declare.

ABSTRACT

Purpose: A history of allergy has been inversely associated with several types of cancer although the evidence is not entirely consistent. We examined the association between allergy history and risk of glioma, meningioma, acoustic neuroma, and parotid gland tumors using data on a large number of cases and controls from five INTERPHONE study countries (Australia, Canada, France, Israel, New Zealand), to better understand potential sources of bias in brain tumor case-control studies and to examine associations between allergy and tumor sites where few studies exist.

Methods: A total of 793 glioma, 832 meningioma, 394 acoustic neuroma, and 84 parotid gland tumor cases were analyzed with 2520 controls recruited during 2000-2004. Conditional logistic regression models were used to obtain odds ratios (ORs) and 95% confidence intervals (CIs) for associations between self-reported allergy and tumor risk.

Results: A significant inverse association was observed between a history of any allergy and glioma (OR = 0.73, 95% CI 0.60-0.88), meningioma (OR = 0.77, 95% CI 0.63-0.93), and acoustic neuroma (OR = 0.64, 95% CI 0.49-0.83). Inverse associations were also observed with specific allergic conditions. However, inverse associations with asthma and hay fever strengthened with increasing age of allergy onset and weakened with longer time since onset. No overall association was observed for parotid gland tumors (OR = 1.21, 95% CI 0.73-2.02).

Conclusions: While allergy history might influence glioma, meningioma, and acoustic neuroma risk, the observed associations could be due to information or selection bias or reverse causality.

Key words: asthma, hay fever, eczema, glioma, meningioma, acoustic neuroma

BACKGROUND

A history of allergy has been inversely associated with several types of neoplasm including brain tumors [1], although the evidence is not entirely consistent. A 2007 meta-analysis of eight studies, involving 3450 glioma and 1070 meningioma cases, reported significant inverse associations, with ORs ranging from 0.6 to 0.7, between a history of any allergy, asthma, eczema and glioma risk but no association with meningioma [2]. National analyses of INTERPHONE data in Germany and the UK reported inverse associations between allergy and risk of glioma and meningioma, but not acoustic neuroma [3-6]. An analysis of data from five INTERPHONE study countries (Denmark, Norway, Finland, Sweden, and southeast England) including 1527 glioma cases and 3309 control subjects reported significant inverse associations (0.65) with a history of asthma, hay fever, and eczema and a significant inverse trend with number of allergic conditions [7]. However, the inverse associations with hay fever and eczema were observed only for current disease and not for those who were clear of disease. No association was observed with acoustic neuroma [8]. Postulated biological mechanisms underlying an inverse association between allergy and cancer risk include enhanced immune function and surveillance, with possible roles for immunoglobulin E (IgE) and allergy-related cytokines [2,9].

However, results from studies with prospectively recorded histories of allergy are inconsistent with those from case-control studies. Results from two cohorts in the Swedish Twin Registry reported both inverse and null associations between allergy and glioma risk, as well as positive associations with meningioma; however there were few incident brain tumors observed [10]. No association was observed between a history of asthma or hay fever and overall brain cancer

mortality in the large-scale Cancer Prevention Study-II involving data on over 1.1 million participants and 2195 brain cancer deaths [11], possibly suggesting some form of reporting bias in case-control studies. There are also conflicting results in case-control studies according to timing of allergy diagnosis and the possibility of reverse causality remains of concern.

Given continued and expanding research into possible allergic influences in cancer [1,9], we sought to examine the association between allergy history and risk of glioma, meningioma, acoustic neuroma, and parotid gland tumors using data on a large number of cases and controls from a consortium of five other INTERPHONE studies (Australia, Canada, France, Israel, and New Zealand) with detailed data on the timing of allergy onset and other study-related factors, such as respondent type and interview quality, to better understand potential sources of bias in brain tumor case-control studies and to examine associations between allergy and tumor sites where few published studies exist, e.g., meningioma, acoustic neuroma, and parotid gland.

METHODS

Study Population

INTERPHONE is a large, 13-country, largely population-based case-control study conducted according to a common protocol. Detailed methods are published elsewhere [12,13]. Cases of primary brain glioma, meningioma, acoustic neuroma, and parotid gland tumors between 30 and 59 years of age at diagnosis were recruited between 2000 and 2004. Glioma, meningioma, and acoustic neuroma cases were identified among residents of major population centers in Australia

(Melbourne, Sydney), Canada (Montreal, Ottawa, Vancouver), France (Lyon, Paris), and New Zealand (Greater Auckland, Hamilton, Rotorua, Tauranga, Napier, Hastings, Wellington, Palmerston North, Christchurch). In Israel, the study was nationwide. Malignant parotid gland cases were recruited in Australia, Canada (all centers), and Israel, and benign parotid gland cases in Canada-Ottawa and Israel only. Incident cases were rapidly recruited from all major treatment centers (with the exception of Paris, where some centers did not participate), and completeness verified through secondary sources. All cases recruited were confirmed histologically or through unequivocal diagnostic imaging. Because of the more favorable prognosis of acoustic neuroma and parotid gland tumors, retrospective case ascertainment up to one year in the past was permitted for these rarer lesions to increase the statistical power of the study.

Controls were randomly selected from electoral lists (Australia, Canada-Montreal, France, New Zealand), health/population registries (Canada-Vancouver, Israel), or random digit dialing (Canada-Ottawa). The original INTERPHONE protocol called for the selection of one control for each case of glioma or meningioma, two controls for acoustic neuroma, and three controls for parotid gland tumors, matched according to five-year age groups, sex, region, and country of birth (Israel only). To maximize statistical power in this analysis, all eligible controls were matched post-hoc to case subjects separately using a matching algorithm that optimized interview time and age group within categories of sex, region, and country of birth (Israel only) [13]. The date of diagnosis for the case was used as the reference date for the control subject in each matched set. Written informed consent was obtained from all study participants prior to the interview. The median (range) number of controls matched to each case was 3 (2-20) for glioma, 3 (1-22) for meningioma, 4 (1-19) for acoustic neuroma, and 8 (2-62) for parotid gland tumors.

Data Collection

Eligible participants were interviewed by trained interviewers using a computer-assisted personal interview (CAPI) questionnaire. If the participant had died or was unable to participate, a proxy respondent was used. The questionnaire captured detailed information on a range of personal and family characteristics. Participants were asked to indicate if they had ever been diagnosed with asthma, hay fever, or eczema, and at what age (years) they experienced their first episode. For eczema, participants were also asked to indicate at what age (years) they stopped having the disease, what proportion of time they were affected, if their eczema appeared when they came in contact with particular substances, and what were the main agents that caused the disease. Participants were also asked if any of their close family members are affected by asthma, hay fever, or eczema.

Statistical Analysis

Conditional logistic regression models were used to obtain adjusted ORs and 95% CIs characterizing the association between allergy history and brain tumors in all five studies combined. Models were stratified by country, region, sex, and five-year age group at the reference date and adjusted for level of educational attainment (high school or less, medium level technical or professional school, university graduate). The independent effect of a history of any allergy diagnosed at least one year prior to the diagnosis or reference date was examined, as well as that of specific allergic conditions (asthma, hay fever, eczema). The reference category

consisted of participants with no diagnosis of asthma, hay fever, or eczema. The mid-point of the reported age at first episode was used where an age range was reported for analyses according to categories of age or time since onset. Adjustment for marital status (single, married, other), cigarette smoking (cigarette smoking status, cigarettes per day, years smoked), and interview year was also attempted, but produced virtually no change (<10%) in regression coefficients (results not presented).

To assess potential reporting biases, sensitivity analyses were conducted examining only self-reported data (excluding proxy interviews), participants who had a high quality interview (as determined by the interviewer), and participants with only in-person interviews (excluding telephone interviews). Sensitivity analyses were also conducted including only study centers with a population-based recruitment strategy, or with higher control response rates ($\geq 60\%$). Multiplicative interaction terms between allergy history and country, sex, age at reference date (< 50 years, ≥ 50 years), and smoking status (ever, never) were entered into the conditional logistic regression models to assess potential effect modification, with two-sided P-values calculated based on the likelihood ratio statistic.

Analyses were conducted using SAS version 9.2 [14]. Ethics approval was obtained from the Ottawa Hospital and from all appropriate national and local research ethics boards as well as from the Ethical Review Board of the International Agency for Research on Cancer (IARC, Lyon) for the INTERPHONE study and of the Municipal Institute for Medical Investigation (IMIM) Barcelona for maintenance and exploitation of the five-country database at CREAL.

RESULTS

Out of a total of 3141 eligible cases (1302 gliomas, 1199 meningiomas, 521 acoustic neuromas, and 119 parotid gland tumors), 2132 were interviewed (809 gliomas, 842 meningiomas, 397 acoustic neuromas, and 84 parotid gland tumors) and formed part of a matched set [13]. Following exclusions of participants with missing data on allergy or educational attainment, 793 glioma, 832 meningioma, 394 acoustic neuroma, and 84 parotid gland tumor cases were retained for analysis; the total number of control subjects ranged from 1074 for parotid gland tumors to 2374 for gliomas.

Table 1 presents selected participant characteristics at enrollment. Glioma cases were more likely to be male (63.3%) and meningioma cases female (74.9%). Meningioma cases also tended to be somewhat older at diagnosis and have a lower level of educational attainment. A total of 17.4% of glioma cases were interviewed by proxy, whereas proxy interviews were less frequent for other tumor types.

A history of any allergy was reported by 25.8% (32.9%) of glioma cases (controls), 26.8% (32.8%) of meningioma cases (controls), and 26.3% (35.6%) of acoustic neuroma cases (controls). For parotid gland tumors (not shown), respective percentages were 35.7% among cases and 26.8% among controls.

There was a significant inverse association between a history of any allergy and risk of glioma (OR = 0.73, 95% CI 0.60-0.88), meningioma (OR = 0.77, 95% CI 0.63-0.93), and acoustic

neuroma (OR = 0.64, 95% CI 0.49-0.83) but not parotid gland tumors (OR = 1.21, 95% CI 0.73-2.02) (Table 2). The inverse association was somewhat stronger in those with a family history of any asthma, hay fever, or eczema for glioma (OR = 0.69, 95% CI 0.54-0.87), but not for meningioma (OR = 0.77, 95% CI 0.62-0.97) or acoustic neuroma (OR = 0.67, 95% CI 0.49-0.91). A history of both personal and family history of allergy was reported by 17.7% (23.8%) of glioma cases (controls), 19.7% (24.2%) of meningioma cases (controls), and 19.6% (26.9%) of acoustic neuroma cases (controls).

Inverse associations were also observed according to specific allergic conditions (Table 2). For asthma, ORs ranged from 0.68 for acoustic neuroma to 0.77 for meningioma; only for glioma was the OR significantly reduced. For hay fever, ORs ranged from 0.67 for glioma to 0.80 for meningioma, with significant reductions for both glioma and acoustic neuroma. For eczema, the reduced ORs (ranging from 0.56 to 0.74) were statistically significant for all three outcomes. ORs were somewhat reduced for a history of contact eczema (glioma OR = 0.60, 95% CI 0.36-1.01; meningioma OR = 0.76, 95% CI 0.49-1.17; acoustic neuroma OR = 0.65 95% CI 0.35-1.22). ORs for all three outcomes tended to be lower among subjects reporting a history of all three allergic conditions.

However, there was some evidence that the inverse associations with asthma and hay fever strengthened with increasing age of allergy onset and weakened with longer time since onset (Table 2). For eczema, the inverse associations tended to be stronger in those with current disease (glioma OR = 0.52, 95% CI 0.33-0.82; meningioma OR = 0.69, 95% CI 0.47-1.00; acoustic neuroma OR = 0.46 95% CI 0.26-0.84) compared to those whose eczema symptoms had

ceased (glioma OR = 0.84, 95% CI 0.57-1.24; meningioma OR = 0.86, 95% CI 0.59-1.25; acoustic neuroma OR = 0.71 95% CI 0.41-1.23).

The inverse associations with allergy were generally stronger for high-grade than low-grade glioma (Table 3). Moreover, there was an inverse gradient in the risk of high grade glioma with number of allergies - although no similar gradient was apparent for low grade gliomas.

Upon restriction to participants with a history of asthma only (44 cases, 130 controls), with no history of hay fever or eczema, the inverse association between asthma and glioma was attenuated (OR = 0.92, 95% CI 0.63-1.33), but persisted for meningioma (OR = 0.72, 95% CI 0.49-1.05) and acoustic neuroma (OR = 0.61 95% CI 0.35-1.08). For participants with a history of hay fever only (75 cases, 270 controls) or eczema only (32 cases, 154 controls), results did not materially change (hay fever only - glioma OR 0.73, 95% CI 0.54-0.97; meningioma OR 0.76, 95% CI 0.56-1.02; acoustic neuroma OR 0.63, 95% CI 0.42-0.94; eczema only - glioma OR 0.68, 95% CI 0.45-1.03; meningioma OR 0.69, 95% CI 0.48-0.99; acoustic neuroma OR 0.55, 95% CI 0.33-0.93).

Sensitivity analyses restricting data to participants who were self-respondents, who had a high quality interview, and who were interviewed in-person produced little change in ORs (Table 4). Results were also insensitive to the exclusion of data from Paris, where recruitment was not completely population-based. However, when restricting the analysis to centers with higher control participation rates ($\geq 60\%$), the inverse relationship for glioma was somewhat attenuated, while those for meningioma and acoustic neuroma were somewhat strengthened.

There was no significant modification of associations by sex, age at reference date, or cigarette smoking status (results not shown); except that for the association between a history of hay fever and meningioma the OR was 0.61 (95% CI 0.44-0.87) in never smoking participants and 1.10 (95% CI 0.77-1.57) in ever smokers (P value for interaction = 0.01). There was no evidence that results varied by country (P values for interaction ranging from 0.75 to 0.89).

DISCUSSION

We report in a large-scale international case-control study with data on 2103 case and 2520 control subjects, apparent risk reductions of 30% for glioma, 20-30% for meningioma, and 30-40% for acoustic neuroma with a history of any allergy and histories of specific allergic conditions. These inverse associations tended to strengthen for asthma and hay fever in those with an older age at allergy onset and, reciprocally, for those with a more recent allergy. For eczema, inverse associations tended to be stronger in those with current compared to past disease. No association was observed for parotid gland tumors.

Although previous case-control studies have reported inverse associations between history of allergy and glioma, and, to a lesser extent, meningioma, there are conflicting results according to timing of diagnosis of allergy. An early six-country case-control study of 1178 glioma cases and 2493 control subjects reported significant inverse associations between a history of any allergy, eczema, other allergies and glioma risk (~ 40% reduction), but there was no trend according to

age at diagnosis or disease duration [15]. Similar results were reported by two smaller US studies [16,17].

However, the German-INTERPHONE study reported inverse associations between any allergy, hay fever, eczema and glioma with an older age at onset or shorter duration of allergy [3]. The Southeast and Northern UK INTERPHONE study also reported significant inverse associations between a history of any allergy and glioma (~40% reduction) as well as with specific allergic conditions which were stronger for those with a recent onset of asthma or eczema [5]. However, for meningioma, the strongest inverse associations were reported for those with an early age of asthma or hay fever onset (< 10 years) [6]. For the UK and Nordic studies combined, inverse associations (~40-50% reductions) between current but not prior allergy, hay fever, eczema and glioma risk were observed, but there was no trend according to age at onset or duration of the condition [7]. We had no data on whether asthma or hay fever symptoms had ceased. A case-control study in the San Francisco Bay Area also reported inverse associations between late-onset (12+ years) respiratory allergy and glioma [18].

There are fewer studies of acoustic neuroma. Brenner et al. [17] in a US case-control study of 96 cases and 799 controls, reported a significant positive association between a history of hay fever and acoustic neuroma (OR = 2.36, 95% CI 1.38-4.03), which was stronger with an older age at diagnosis or shorter disease duration. Combined results from the UK and Nordic INTERPHONE studies indicated no association between a history of allergy and acoustic neuroma overall or according to disease duration [8].

Findings of inverse associations strengthening in those with both an older age at allergy onset and more recent allergy here and in previous national analyses of INTERPHONE data may be due to either the importance of recent immunological status for cancer or conversely, the suppression of allergic symptoms by the developing tumor, or some combination of both. For glioma, both local and systemic immunosuppression is observed [19-20]. Schwartzbaum et al. [19] observed widespread down-regulation in allergy and inflammation gene expression with increasing glioblastoma progression in an analysis of microarray tissue sample data from 142 patients; however longitudinal data are needed. It is unlikely however, that reverse causality can explain findings at other tumor sites with minimal immunosuppressive effects. There are also allergic and non-allergic forms of asthma, hay fever, and eczema with distinct clinical and immunological features and asthma diagnosed later in life is more likely non-allergic compared to asthma diagnosed during childhood [21-22].

In this study strong inverse associations with allergy were observed for each of glioma, meningioma, and acoustic neuroma (but not parotid gland tumors), three tumors with distinct clinical and pathogenic profiles, possibly suggesting some sort of reporting bias in retrospective allergy ascertainment by case and control participants. Further, in support of a reporting bias explanation are results from studies with prospectively collected data on allergy history. The Swedish Twin Registry observed both inverse and null associations between allergy history and glioma risk, as well as positive associations with meningioma [10]. There was also no association observed between a history of asthma or hay fever and overall brain cancer mortality in the large-scale Cancer Prevention Study-II [11]. However there was no data on the timing of diagnosis or duration of allergy. Allergy history may be underreported by proxy respondents for

glioma cases [10]; however results here and in a previous meta-analysis were insensitive to the exclusion of proxy interviews [2]. There is also the possibility of cognitive impairment for high-grade glioma cases leading to underreporting of prior allergies. However, results were similar when examining only subjects with a high quality interview. Results were also of a comparable magnitude across all three tumor sites. The prevalence of any allergy (ranging from 25.8-35.7% of cases and 26.8-35.6% of controls) is similar to that reported in previous studies [23].

To address potential reporting biases, some studies have examined biological indicators of allergic status [18, 24-27]. A case-control study of 169 glioma cases and 520 controls nested in four prospective cohorts reported a significant inverse association between borderline (OR = 0.63, 95% CI 0.42-0.93) but not elevated total IgE levels. There was also no association with food- or respiratory-specific IgE [26]. A case-control study of 275 glioma, 175 meningioma, and 49 acoustic neuroma cases, and 963 control subjects nested in the European Prospective Investigation into Cancer (EPIC) reported an inverse association between elevated respiratory-specific IgE concentrations and glioma (OR = 0.73, 95% CI 0.51-1.06) but not meningioma or acoustic neuroma [27]. More recently, in a nested case-control study of 594 glioma cases and 1177 matched controls in Norway, significant inverse associations were observed between elevated respiratory-specific IgE concentrations and glioblastoma risk among women (OR = 0.46, 95% CI 0.23-0.93) and total IgE concentrations and glioma risk in both men and women combined, both overall (OR = 0.75, 95% CI 0.56-0.99) as well as for concentrations 20 years prior to diagnosis (OR = 0.54, 95% CI 0.30-0.99) [28]. However, questions regarding the utility of this biomarker remain, including typically low levels of concordance with self-reported allergy and changing levels of IgE over time [18,24,29,30]. Other studies examined

concentrations of immune regulatory proteins [31] or polymorphisms in allergy-related genes in relation to glioma risk [32-38]. In two studies, the inverse association between allergy and glioma was modified by genotype [33,35].

There may also be potential selection biases, particularly as response rates in the INTERPHONE study tended to be low among controls (ranging from 35-74%). In previous research, a meta-analysis of studies of childhood leukemia reported that inverse associations observed with allergy history were attenuated when restricting the analysis to studies with case and control response rates of $\geq 80\%$ [39]. When we considered only centers with higher control response levels here (defined as $\geq 60\%$), results were attenuated for glioma, but strengthened for acoustic neuroma; differences however, were small. There was also a tendency for controls to be more highly educated than case subjects, however adjustment for level of education here resulted only in modest changes in ORs.

We lacked data on allergy medication use. Scheurer et al. [40] reported a significant three-fold increase in glioma risk for those with a history of long-term antihistamine use and a prior asthma or allergy history in a US case-control study of 325 glioma cases and 600 control subjects.

In conclusion, we observed inverse associations between a history of allergy and the risk of glioma, meningioma, and acoustic neuroma, but possible information or selection bias and reverse causality, cannot be ruled out as possible explanations for these findings. Further work is needed including sufficiently large studies with detailed prospectively-collected information on

indicators of allergy, allergy onset and cessation, and allergy medication use including multiple specific biomarkers of allergy and immune function.

ACKNOWLEDGEMENTS

Funding for the INTERPHONE Study was provided by the European Fifth Framework Program, ‘Quality of Life and Management of Living Resources’ (contract QLK4-CT-1999901563), the International Union against Cancer (UICC). The UICC received funds for this purpose from the Mobile Manufacturers’ Forum and GSM Association. Provision of funds to the INTERPHONE Study investigators via the UICC was governed by agreements that guaranteed INTERPHONE’s complete scientific independence. The terms of these agreements are publicly available at <http://www.iarc.fr/en/research-groups/RAD/RCAd.html>. The Australian center was supported by the National Health and Medical Research Council (EME grant 219129); BKA was supported by a University of Sydney Medical Foundation Program Grant. The Cancer Council NSW and the Cancer Council Victoria provided most of the infrastructure for the project in Australia. The Canada-Montreal data collection was funded by a grant from the Canadian Institutes of Health Research (CIHR) (project MOP-42525). Additionally, JS’s research team was partly funded by the Canada Research Chair programme and by the Guzzo-CRS Chair in Environment and Cancer. The other Canadian centers were supported by a university-industry partnership grant from the CIHR, the latter including partial support from the Canadian Wireless Telecommunications Association. The CIHR university-industry partnerships program also includes provisions that ensure complete scientific independence of the investigators. DK is the Natural Sciences and Engineering Research Council (NSERC) Chair in Risk Science at the University of Ottawa. Additional funding for the study in France was provided by l’Association pour la Recherche sur le Cancer (ARC) (contract 5142) and three network operators (Orange, SFR, Bouygues Telecom). The funds provided by the operators represented 5% of the total cost

of the French study and were governed by contracts guaranteeing the complete scientific independence of the investigators. In New Zealand, funding was provided by the Health Research Council, Hawkes Bay Medical Research Foundation and the Cancer Society of New Zealand.

The authors would like to acknowledge Jordi Figuerola Alquezar (CREAL) for programming and database management support. The Australian team would like to acknowledge the overall support given to study design and implementation by Michael Besser and Andrew Kaye; and to thank fieldwork staff in Melbourne - Monique Kilkenny, Georgina Marr, Tracey McPhail, Fiona Phillips, Hayley Shaw, Yvonne Torn-Broers; and Sydney - Matthew Carroll, Sally Dunlop, Virginia MacDonald and Elizabeth Willows - the many interviewers for their hard work, and the NSW and Victorian Cancer Registries for aiding case identification. We also thank Angus Cook (University of Western Australia) and Neil Pearce (London School of Hygiene and Tropical Medicine) who, together with Alistair Woodward, were responsible for the conduct of the INTERPHONE Study in New Zealand. The Canada-Ottawa center gratefully acknowledges the work of Lynn Pratt and Daniel Bedard for their leading roles in study coordination. The Canada-Montreal team acknowledges Louise Nadon and the diligent work of fieldwork staff including Marie-Claire Goulet, Sylvie Plante, Sally Campbell, and the interviewer team. The following hospitals and physicians in Montreal permitted access to their patients: CHUM Hopital Notre-Dame (Dr Wieslaw Michel Bojanowski, Dr Jean Jacques Dufour, Dr Francois Lavigne, Dr Robert A Moumdjian); Neurological Institute of Montreal (Dr Rolando Del Maestro, Dr Richard Leblanc); Hopital du Sacre-Coeur de Montreal (Dr Marc F Giroux); The Jewish General Hospital (Dr Gerard Mohr, Dr Jamie Miles Rappaport). The Canada-Vancouver center wishes to

acknowledge the work carried out by Dr Alison Pope, Patricia Nelson, Nelson Ha, Dr Kaushik Bhagat and the interviewer team. The French team to thank the French fieldwork team, Mary-Pierre Herrscher, Fatima Lamri, Agnes Boidart, Helene Gire, Juliette Krassilchik, Judith Lenti, Delphine Maillac, Frederique Sonnet, Flore Taguiev, Julie Frantz, France Castay, Florian Gay, for their excellent work. The Israeli team acknowledges the diligent work of the fieldwork and office staff including Etti Aviezer, Tehila Ben-Tal, Meirav Dolev, Yonit Deutch, Tamara Rodkin, Ahuva Zultan and the interviewer team.

REFERENCES

1. Turner MC (2012) Epidemiology: Allergy history, IgE and cancer. *Cancer Immunol Immunother* 61:1493-1510.
2. Linos E, Raine T, Alosno A, Michaud D (2007) Atopy and risk of brain tumors: a meta-analysis. *J Natl Cancer Inst* 99:1544-1550.
3. Berg-Beckhoff G, Schuz J, Blettner M, Munster E, Schlaefer K, Wahrendorf J, Schlehofer B (2009) History of allergic disease and epilepsy and risk of glioma and meningioma (INTERPHONE study group, Germany). *Eur J Epidemiol* 24:433-440.
4. Schlehofer B, Schlaefer K, Blettner M, Berg G, Bohler E, Hettinger I, Kunna-Grass K, Wahrendorf J, Schuz J, Interphone Study Group (2007) Environmental risk factors for sporadic acoustic neuroma (Interphone Study Group, Germany). *Eur J Cancer* 43:1741-1747.
5. Schoemaker MJ, Swerdlow AJ, Hepworth SJ, McKinney PA, van Tongeren M, Muir KR (2006) History of allergies and risk of glioma in adults. *Int J Cancer* 119:2165-2172.
6. Schoemaker MJ, Swerdlow AJ, Hepworth SJ, van Tongeren M, Muir KR, McKinney PA (2007) History of allergic disease and risk of meningioma. *Am J Epidemiol* 165:477-485.
7. Wigertz A, Lonn S, Schwartzbaum J, Hall P, Auvinen A, Christensen HC, Johansen C, Klaeboe L, Salminen T, Schoemaker MJ, Swerdlow AJ, Tynes T, Feychting M (2007) Allergic conditions and brain tumor risk. *Am J Epidemiol* 166:941-950.
8. Schoemaker MJ, Swerdlow AJ, Auvinen A, Christensen HC, Feychting M, Johansen C, Klaeboe L, Lonn S, Salminen T, Tynes T (2006) Medical history, cigarette smoking and risk of acoustic neuroma: an international case-control study. *Int J Cancer* 120:103-110.
9. Jensen-Jarolim E, Achatz G, Turner MC, Karagiannis S, Legrand F, Capron M, Penichet ML, Rodriguez JA, Siccardi AG, Vangelista L, Riemer AB, Gould H (2008) AllergoOncology: the role of IgE-mediated allergy in cancer. *Allergy* 63:1255-1266.
10. Schwartzbaum J, Jonsson F, Ahlbom A, Preston-Martin S, Lonn S, Soderberg KC, Feychting M (2003) Cohort studies of association between self-reported allergic conditions, immune-related diagnoses and glioma and meningioma risk. *Int J Cancer* 106:423-428.
11. Turner MC, Chen Y, Krewski D, Ghadirian P, Thun MJ, Calle EE (2005) Cancer mortality among US men and women with asthma and hay fever. *Am J Epidemiol* 162:212-221.
12. Cardis E, Richardson L, Deltour I, Armstrong B, Feychting M, Johansen C, Kilkenny M, McKinney P, Modan B, Sadetzki S, Schuz J, Swerdlow A, Vrijheid M, Auvinen A, Berg G, Blettner M, Bowman J, Brown J, Chetrit A, Christensen HC, Cook A, Hepworth S, Giles G, Hours M, Iavarone I, Jarus-Hakak A, Klaeboe L, Krewski D, Lagorio S, Lonn S, et al.

- (2007) The INTERPHONE study: design, epidemiological methods, and description of the study population. *Eur J Epidemiol* 22:647-664.
13. Cardis E, Armstrong BK, Bowman JD, Giles GG, Hours M, Krewski D, McBride M, Parent ME, Sadetzki S, Woodward A, Brown J, Chetrit A, Figuerola J, Hoffmann C, Jarushak A, Montestruq L, Nadon L, Richardson L, Villegas R, Virjheid M (2011) Risk of brain tumours in relation to estimated RF dose from mobile phones: results from five Interphone countries. *Occup Environ Med* 68:631-640.
 14. SAS Institute, Inc (2008) SAS, version 9.2. Cary, NC: SAS Institute, Inc.
 15. Schlehofer B, Blettner M, Preston-Martin S, Niehoff D, Wahrendorf J, Arslan A, Ahlbom A, Choi WN, Giles GG, Howe GR, Little J, Menegoz F, Ryan P (1999) Role of medical history in brain tumor development. Results from the International Adult Brain Tumor Study. *Int J Cancer* 82:155-160.
 16. McCarthy BJ, Rankin K, Il'yasova D, Erdal S, Vick N, Ali-Osman F, Bigner DD, Davis F (2011) Assessment of type of allergy and antihistamine use in the development of glioma. *Cancer Epidemiol Biomarkers Prev* 20:370-378.
 17. Brenner AV, Linet MS, Fine HA, Shapiro WR, Selker RG, Black PM, Inskip PD (2002) History of allergies and autoimmune diseases and risk of brain tumors in adults. *Int J Cancer* 99:252-259.
 18. Wiemels JL, Wiencke JK, Patoka J, Moghadassi M, Chew T, McMillan A, Miike R, Barger G, Wrensch M (2004) Reduced immunoglobulin E and allergy among adults with glioma compared with controls. *Cancer Res* 64:8468-8473.
 19. Schwartzbaum JA, Huang K, Lawler S, Ding B, Yu J, Chiocca EA (2010) Allergy and inflammatory transcriptome is predominantly negatively correlated with CD133 expression in glioblastoma. *Neuro Oncol* 12:320-327.
 20. Avril T, Vauleon E, Tanguy-Royer S, Mosser J, Quillien V (2011) Mechanisms of immunomodulation in human glioblastoma. *Immunotherapy* 3(4 Suppl):42-44.
 21. Anto JM, Pinart M, Akdis M, Auffray C, Bachert C, Basagana X, Carlsen KH, Guerra S, von Hertzen L, Illi S, Kauffmann F, Keil T, Kiley JP, Koppelman GH, Lupinek C, Martinez FD, Nawijn MC, Postma DS, Siroux V, Smit HA, Sterk PJ, Sunyer J, Valenta R, Valverde S, Akdis CA, Annesi-Maesano I, Ballester F, Benet M, Cambon-Thomsen A, Chatzi L, et al. (2012) Understanding the complexity of IgE-related phenotypes from childhood to young adulthood: A Mechanisms of the Development of Allergy (MeDALL) Seminar. *J Allergy Clin Immunol* 129:943-954.
 22. Novak N, Bieber T (2003) Allergic and nonallergic forms of atopic diseases. *J Allergy Clin Immunol* 112:252-262.

23. Il'yasova D, McCarthy B, Marcello J, Schildkraut JM, Moorman PG, Krishnamachari B, Ali-Osman F, Bigner DD, Davis F (2009) Association between glioma and history of allergies, asthma, and eczema: a case-control study with three groups of controls. *Cancer Epidemiol Biomarkers Prev* 18:1232-1238.
24. Wiemels JL, Wrensch M, Sison JD, Zhou M, Bondy M, Calvocoressi L, Black PM, Yu H, Schildkraut JM, Claus EB (2011) Reduced allergy and immunoglobulin E among adults with intracranial meningioma compared to controls. *Int J Cancer* 129:1932-1939.
25. Wiemels JL, Wilson D, Patil C, Patoka J, McCoy L, Rice T, Schwartzbaum J, Heimberger A, Samson JH, Chang S, Prados M, Wiencke JK, Wrensch M (2009) IgE, allergy, and risk of glioma: Update from the San Francisco Bay Area Adult Glioma Study in the Temozolomide era. *Int J Cancer* 125:680-687.
26. Calboli FC, Cox DG, Buring JE, Gaziano JM, Ma J, Stampfer M, Willett WC, Tworoger SS, Hunter DJ, Camargo CA Jr, Michaud DS (2011) Prediagnostic plasma IgE levels and risk of adult glioma in four prospective cohort studies. *J Natl Cancer Inst* 103:1588-1595.
27. Schlehofer B, Siegmund B, Linseisen J, Schuz J, Rohrmann S, Becker S, Michaud D, Melin B, Bas Bueno-de-Mesquita H, Peeters PH, Vineis P, Tjonneland A, Olsen A, Overvad K, Romieu I, Boeing H, Aleksandrova K, Trichopoulou A, Bamia C, Lagiou P, Sacerdote C, Palli D, Panico S, Sieri S, Tumino R, Sanchez MJ, Rodriguez L, Dorronsoro M, Duell EJ, Chirlaque MD, et al. (2011) Primary brain tumours and specific serum immunoglobulin E: a case-control study nested in the European Prospective Investigation into Cancer and Nutrition cohort. *Allergy* 66:1434-1441.
28. Schwartzbaum J, Ding B, Johannesen TB, Osnes LTN, Karavodin L, Ahlbom A, Feychting M, Grimsrud TK (2012) Association between prediagnostic IgE levels and risk of glioma. *J Natl Cancer Inst* 104:1251-1259.
29. Carosso A, Bugiani M, Migliore E, Anto JM, DeMarco R (2007) Reference values of total serum IgE and their significance in the diagnosis of allergy in young European adults. *Int Arch Allergy Immunol* 142:230-238.
30. Hoppin JA, Jaramillo R, Salo P, Sandler DP, London SJ, Zeldin DC (2011) Questionnaire predictors of atopy in a US population sample: findings from the National Health and Nutrition Examination Survey, 2005-2006. *Am J Epidemiol* 173:544-552.
31. Zhou M, Wiemels JL, Bracci PM, Wrensch MR, McCoy LS, Rice T, Sison JD, Patoka JS, Wiencke JK (2010) Circulating levels of the innate and humoral immune regulators CD14 and CD23 are associated with adult glioma. *Cancer Res* 70:7534-7542.
32. Dobbins SE, Hosking FJ, Shete S, Armstrong G, Swerdlow A, Liu Y, Yu R, Lau C, Schoemaker MJ, Hepworth SJ, Miur K, Bondy M, Houlston RS (2011) Allergy and glioma risk: test of association by genotype. *Int J Cancer* 128:1736-1740.

33. Lachance DH, Yang P, Johnson DR, Decker PA, Kollmeyer TM, McCoy LS, Rice T, Xiao Y, Ali-Osman F, Wang F, Stoddard SM, Sprau DJ, Kosel ML, Wiencke JK, Wiemels JL, Patoka JS, Davis F, McCarthy B, Rynearson AL, Worra JB, Fridley BL, O'Neill BP, Buckner JC, Il'yasova D, Jenkins RB, Wrensch MR (2011) Associations of high-grade glioma with glioma risk alleles and histories of allergy and smoking. *Am J Epidemiol* 174:574-581.
34. Ruan Z, Zhao Y, Yan L, Chen H, Fan W, Chen J, Wu Q, Qian J, Zhang T, Zhou K, Mao Y, Zhou L, Huang Y, Lu D (2011) Single nucleotide polymorphisms in IL-4Ra, IL-13 and STAT6 genes occurs in brain glioma. *Front Biosci (Elite Ed)* 3:33-45.
35. Schoemaker MJ, Robertson L, Wigertz A, Jones ME, Hosking FJ, Feychting M, Lonn S, McKinney PA, Hepworth SJ, Muir KR, Auvinen A, Slaminen T, Kiuru A, Johansen C, Houlston RS, Swerdlow AJ (2010) Interaction between 5 genetic variants and allergy in glioma risk. *Am J Epidemiol* 171:1165-1173.
36. Schwartzbaum J, Ahlbom A, Malmer B, Lonn S, Brookes AJ, Doss H, Debinski W, Henriksson R, Feychting M (2005) Polymorphisms associated with asthma are inversely related to glioblastoma multiforme. *Cancer Res* 65:6459-6465.
37. Schwartzbaum JA, Ahlbom A, Lonn S, Malmer B, Wigertz A, Auvinen A, Brookes AJ, Collatz Christensen H, Henriksson R, Johansen C, Salminen T, Schoemaker MJ, Swerdlow AJ, Debinski W, Feychting M (2007) An international case-control study of interleukin-4Ra, interleukin-13, and cyclooxygenase-2 polymorphisms and glioblastoma risk. *Cancer Epidemiol Biomarkers Prev* 16:2448-2454.
38. Wiemels JL, Wiencke JK, Kelsey KT, Moghadassi M, Rice T, Urayama KY, Miike R, Wrensch M (2007) Allergy-related polymorphisms influence glioma status and serum IgE levels. *Cancer Epidemiol Biomarkers Prev* 16:1229-1235.
39. Linabery AM, Jurek AM, Duval S, Ross JA (2010) The association between atopy and childhood/adolescent leukemia: a meta-analysis. *Am J Epidemiol* 171:749-764.
40. Scheurer ME, El-Zein R, Thompson PA, Aldape KD, Levin VA, Gilbert MR, Weinberg JS, Bondy ML (2008) Long-term anti-inflammatory and antihistamine medication use and adult glioma risk. *Cancer Epidemiol Biomarkers Prev* 17:1277-1281.

Table 1. Characteristics of participant case and control subjects at enrollment, INTERPHONE study countries: Australia, Canada, France, Israel, and New Zealand.

Characteristic	Glioma		Meningioma		Acoustic Neuroma		Parotid Gland	
	Cases (n = 793) %	Controls (n = 2374) %	Cases (n = 832) %	Controls (n = 2252) %	Cases (n=394) %	Controls (n=1436) %	Cases (n=84) %	Controls (n=1074) %
Sex								
Male	63.3	45.8	25.1	41.9	50.3	47.3	50.0	47.5
Female	36.7	54.3	74.9	58.1	49.8	52.7	50.0	52.6
Age at reference date								
<=34	9.2	5.9	3.9	4.7	4.8	5.8	11.9	8.3
35-39	10.7	10.5	6.0	9.6	11.9	10.9	17.9	8.4
40-44	16.7	15.8	12.6	14.7	17.3	16.1	19.1	13.7
45-49	17.2	17.8	21.2	19.5	20.1	19.2	11.9	17.0
50-54	22.8	24.7	28.1	25.0	24.9	24.4	20.2	22.3
55+ years	23.5	25.3	28.3	26.6	21.1	23.6	19.1	30.5
Education								
High School or less	43.0	40.4	51.1	40.3	47.5	41.4	41.7	36.5
Medium level technical school	25.6	23.9	23.6	24.1	23.6	23.5	31.0	23.9
University	31.4	35.8	25.4	35.6	28.9	35.1	27.4	39.6
Country								
Australia	37.1	28.1	30.1	28.6	32.2	43.3	8.3	5.7
Canada	21.1	25.1	11.3	23.5	21.3	23.3	67.9	48.7
France	11.7	18.7	16.8	18.6	27.7	14.8	0.0	-
Israel	19.9	22.2	36.1	24.6	15.0	16.6	23.8	45.6
New Zealand	10.2	6.0	5.8	4.8	3.8	2.0	0.0	-
Interview location								
Hospital	13.2	0.7	16.8	0.7	6.1	0.4	2.4	0.8
Home	74.7	68.8	73.3	69.3	68.5	68.1	66.7	70.9
Other/missing	12.1	30.5	9.9	29.9	25.4	31.5	31.0	28.3
Proxy interviews	17.4	0.4	2.0	0.4	0.2	0.4	2.4	0.2

Table 2. Adjusted ORs (95% CIs) for glioma, meningioma, and acoustic neuroma in relation to a history of any allergy or specific allergic condition (asthma, hay fever, eczema), INTERPHONE study countries: Australia, Canada, France, Israel, and New Zealand.

Allergy	Glioma				Meningioma				Acoustic Neuroma			
	Cases	Controls	OR	95% CI ^a	Cases	Controls	OR	95% CI ^a	Cases	Controls	OR	95% CI ^a
No allergy	567	1580	1.00 (ref)	-	602	1497	1.00 (ref)	-	288	915	1.00 (ref)	-
Any allergy	197	774	0.73	(0.60-0.88)	220	731	0.77	(0.63-0.93)	103	505	0.64	(0.49-0.83)
No allergy	567	1557	1.00 (ref)	-	602	1461	1.00 (ref)	-	287	911	1.00 (ref)	-
Asthma	74	275	0.72	(0.54-0.96)	82	260	0.78	(0.59-1.03)	36	171	0.68	(0.45-1.02)
Age at onset												
<10 years	30	87	0.85	(0.55-1.33)	25	81	0.87	(0.54-1.40)	16	51	0.99	(0.53-1.82)
10-19 years	15	39	0.86	(0.45-1.64)	16	39	1.23	(0.65-2.33)	5	21	0.63	(0.23-1.75)
20+ years	29	146	0.58	(0.38-0.89)	41	138	0.64	(0.44-0.94)	14	93	0.52	(0.28-0.95)
Time since onset												
<10 years	9	64	0.38	(0.18-0.79)	21	57	0.81	(0.48-1.38)	7	45	0.54	(0.24-1.24)
10-19 years	14	60	0.60	(0.32-1.12)	12	54	0.47	(0.24-0.91)	7	33	0.65	(0.28-1.51)
20+ years	51	148	0.89	(0.63-1.26)	49	145	0.89	(0.62-1.26)	22	85	0.77	(0.46-1.29)
No allergy	567	1575	1.00 (ref)	-	602	1496	1.00 (ref)	-	288	895	1.00 (ref)	-
Hay Fever	115	457	0.67	(0.53-0.86)	130	428	0.80	(0.63-1.01)	64	299	0.68	(0.49-0.94)
Age at onset												
<10 years	28	79	0.93	(0.58-1.49)	21	75	0.74	(0.44-1.25)	10	38	1.15	(0.54-2.46)
10-19 years	39	136	0.69	(0.47-1.02)	45	131	1.03	(0.71-1.51)	15	92	0.45	(0.24-0.81)
20+ years	48	238	0.56	(0.40-0.79)	64	216	0.68	(0.50-0.94)	38	156	0.74	(0.49-1.10)
Time since onset												
<10 years	11	86	0.31	(0.16-0.61)	14	69	0.46	(0.25-0.85)	11	51	0.60	(0.30-1.20)
10-19 years	22	81	0.75	(0.45-1.23)	19	73	0.59	(0.35-1.02)	12	53	0.74	(0.38-1.45)
20+ years	82	286	0.75	(0.57-1.00)	96	277	0.95	(0.72-1.24)	40	181	0.70	(0.47-1.03)
No allergy	567	1562	1.00 (ref)	-	602	1448	1.00 (ref)	-	287	874	1.00 (ref)	-
Eczema	62	287	0.67	(0.49-0.91)	82	272	0.74	(0.56-0.98)	34	165	0.56	(0.37-0.85)
Age at onset												
<10 years	19	83	0.66	(0.38-1.12)	21	74	0.70	(0.42-1.19)	11	40	0.90	(0.44-1.83)
10-19 years	13	58	0.67	(0.36-1.25)	23	56	1.01	(0.60-1.69)	11	34	0.84	(0.41-1.71)
20+ years	30	145	0.70	(0.46-1.08)	38	142	0.65	(0.44-0.96)	11	89	0.31	(0.16-0.60)
Time since onset												
<10 years	8	48	0.57	(0.26-1.26)	16	50	0.88	(0.48-1.61)	6	37	0.40	(0.16-0.99)
10-19 years	14	53	0.64	(0.34-1.19)	10	49	0.45	(0.22-0.91)	3	29	0.28	(0.08-0.92)

20+ years	40	182	0.71	(0.49-1.03)	56	172	0.78	(0.56-1.09)	25	97	0.71	(0.43-1.15)
No allergy	567	1580	1.00 (ref)	-	602	1497	1.00 (ref)	-	288	915	1.00 (ref)	-
One allergy	151	562	0.77	(0.62-0.96)	157	530	0.74	(0.59-0.91)	75	369	0.63	(0.47-0.85)
Two allergies	38	167	0.63	(0.43-0.93)	52	159	0.88	(0.62-1.24)	25	110	0.74	(0.46-1.19)
Three allergies	8	45	0.53	(0.24-1.14)	11	42	0.77	(0.38-1.57)	3	26	0.35	(0.10-1.21)

^a OR estimated using conditional logistic regression models stratified by country, region, sex, and five-year age group at the reference date and adjusted for level of educational attainment.

Table 3. Adjusted ORs (95% CIs) for high-grade and low-grade glioma in relation to a history of any allergy or specific allergic conditions (asthma, hay fever, eczema), INTERPHONE study countries: Australia, Canada, France, Israel, and New Zealand.

Allergy	High-grade glioma				Low-grade glioma			
	Cases	Controls	OR	95% CI ^a	Cases	Controls	OR	95% CI ^a
No allergy	379	1505	1.00 (ref)	-	186	1366	1.00 (ref)	-
Any allergy	123	736	0.69	(0.55-0.87)	72	649	0.77	(0.57-1.04)
No allergy	379	1475	1.00 (ref)	-	186	1283	1.00 (ref)	-
Asthma	43	259	0.62	(0.43-0.88)	30	215	0.89	(0.58-1.37)
Age at onset								
<10 years	24	81	0.99	(0.61-1.62)	6	70	0.55	(0.23-1.31)
10-19 years	6	37	0.55	(0.22-1.35)	9	31	1.44	(0.62-3.34)
20+ years	13	136	0.37	(0.20-0.67)	15	105	0.97	(0.54-1.76)
Time since onset								
<10 years	8	115	0.23	(0.11-0.50)	4	49	0.50	(0.17-1.47)
10-19 years	8	115	0.23	(0.11-0.50)	10	41	1.45	(0.67-3.12)
20+ years	35	139	0.92	(0.61-1.37)	16	117	0.86	(0.49-1.52)
No allergy	379	1505	1.00 (ref)	-	186	1309	1.00 (ref)	-
Hay Fever	72	437	0.64	(0.48-0.86)	42	370	0.70	(0.48-1.02)
Age at onset								
<10 years	15	74	0.78	(0.43-1.42)	13	67	1.14	(0.59-2.23)
10-19 years	23	128	0.61	(0.38-0.99)	15	113	0.78	(0.43-1.42)
20+ years	34	217	0.59	(0.40-0.88)	14	179	0.51	(0.28-0.91)
Time since onset								
<10 years	6	76	0.26	(0.11-0.62)	5	63	0.45	(0.17-1.17)
10-19 years	14	73	0.67	(0.36-1.24)	8	61	0.94	(0.43-2.08)
20+ years	52	275	0.73	(0.53-1.03)	29	235	0.73	(0.47-1.13)
No allergy	379	1493	1.00 (ref)	-	186	1345	1.00 (ref)	-
Eczema	32	273	0.53	(0.36-0.79)	29	230	0.93	(0.60-1.45)
Age at onset								
<10 years	9	78	0.45	(0.22-0.93)	10	63	1.12	(0.54-2.33)
10-19 years	7	53	0.55	(0.24-1.24)	6	44	0.85	(0.35-2.05)
20+ years	16	129	0.58	(0.33-1.02)	13	105	0.95	(0.50-1.80)
Time since onset								
<10 years	6	38	0.68	(0.28-1.69)	9	79	0.72	(0.34-1.52)
10-19 years	7	47	0.51	(0.23-1.17)	9	79	0.72	(0.34-1.52)
20+ years	19	174	0.50	(0.30-0.83)	20	140	1.10	(0.66-1.85)
No allergy	379	1505	1.00 (ref)	-	186	1366	1.00 (ref)	-
One allergy	101	536	0.78	(0.60-1.00)	49	462	0.73	(0.51-1.03)
Two allergies	22	200	0.45	(0.28-0.72)	17	151	0.81	(0.47-1.40)
Three allergies	22	200	0.45	(0.28-0.72)	6	36	1.18	(0.48-2.91)

^aOR estimated using conditional logistic regression models stratified by country, region, sex, and five-year age group at the reference date and adjusted for level of educational attainment. Note some adjacent cells collapsed due to small sample sizes in individual cells.

Table 4. Sensitivity analysis of adjusted ORs (95% CIs) for glioma, meningioma, and acoustic neuroma in relation to a history of any allergy according to interview and recruitment characteristics, INTERPHONE study countries: Australia, Canada, France, Israel, and New Zealand.

Allergy	Glioma				Meningioma				Acoustic Neuroma			
	Cases	Controls	OR	95% CI ^a	Cases	Controls	OR	95% CI ^a	Cases	Controls	OR	95% CI ^a
Baseline analysis												
No allergy	567	1580	1.00 (ref)	-	602	1497	1.00 (ref)	-	288	915	1.00 (ref)	-
Any allergy	197	774	0.73	(0.60-0.88)	220	731	0.77	(0.63-0.93)	103	505	0.64	(0.49-0.83)
Self-respondents												
No allergy	475	1553	1.00 (ref)	-	589	1484	1.00 (ref)	-	287	910	1.00 (ref)	-
Any allergy	178	767	0.76	(0.62-0.93)	216	729	0.76	(0.62-0.92)	103	504	0.64	(0.49-0.83)
High quality interviews only												
No allergy	445	1393	1.00 (ref)	-	503	1342	1.00 (ref)	-	259	805	1.00 (ref)	-
Any allergy	155	683	0.71	(0.57-0.89)	180	651	0.77	(0.62-0.95)	93	435	0.66	(0.50-0.87)
In-person interviews												
No allergy	558	1523	1.00 (ref)	-	598	1444	1.00 (ref)	-	279	878	1.00 (ref)	-
Any allergy	195	748	0.73	(0.60-0.88)	216	706	0.76	(0.62-0.92)	101	487	0.65	(0.50-0.85)
Population-based ^b												
No allergy	522	1380	1.00 (ref)	-	533	1299	1.00 (ref)	-	223	816	1.00 (ref)	-
Any allergy	178	639	0.73	(0.59-0.90)	190	601	0.79	(0.64-0.97)	81	439	0.68	(0.50-0.91)
Higher response rates ^c												
No allergy	261	934	1.00 (ref)	-	397	939	1.00 (ref)	-	169	486	1.00 (ref)	-
Any allergy	74	381	0.80	(0.59-1.08)	101	373	0.74	(0.56-0.96)	47	217	0.55	(0.38-0.82)

^a OR calculated using conditional logistic regression models stratified by country, region, sex, and five-year age group at the reference date and adjusted for level of educational attainment.

^b France (Paris) excluded.

^c Australia, Canada (Vancouver), New Zealand excluded.